Drug Database
CA

calcitonin (Fortical Injection / Forcaltonin)

✓ Approved

Kyowa Kirin Co., Ltd. · CALCR · 重组蛋白

什么是 calcitonin?

calcitonin 是一种重组蛋白,由Kyowa Kirin Co., Ltd.研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Subcutaneous Injection。

药物档案

商品名Fortical Injection, Forcaltonin
公司Kyowa Kirin Co., Ltd.
药物类别重组蛋白
分子靶点CALCR
给药途径Injectable (Others), Subcutaneous Injection
状态Approved

作用机制

分子靶点

calcitonin 作用于 1 个分子靶点:

CALCRcalcitonin receptor (CT-R, CTR)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

calcitonin 针对 3 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Endocrine disordersHypercalcaemia of malignancy✓ Approved
Musculoskeletal and connective tissue disordersOsteitis deformans✓ Approved
Musculoskeletal and connective tissue disordersOsteoporosis✓ Approved

相关研究文献

PubMedCNS drugs2026-11-19

Incidence and Factors Associated with Newly Recorded Database-Defined Central Nervous System-Related Diagnoses During and Shortly After Metronidazole Therapy: A Large-Scale Japanese Hospital-Based Administrative Claims Database Study.

Takada Keisuke K, Imai Shungo S, Enoki Yuki Y, Igarashi Yuki Y et al.

Metronidazole (MNZ) is widely used to treat anaerobic and protozoal infections. However, evidence regarding the factors associated with newly recorded, database-defined central nervous system (CNS)-related diagnoses during or shortly after MNZ therapy remains limited. This study evaluated the incidence of newly recorded, database-defined CNS-related diagnoses during and shortly after MNZ therapy and identified the associated factors using a Japanese hospital-based administrative claims database. This retrospective cohort study used the JMDC hospital-based administrative claims database from April 2014 to August 2022. Adults prescribed oral or injectable MNZ were included. The primary outcome was a newly recorded, database-defined CNS-related diagnosis during the risk period after MNZ initiation. Prespecified factors were evaluated using conventional and Firth-penalized Cox proportional hazards regression. Among 58,195 patients, 59 (0.1%) had a newly recorded, database-defined CNS-related diagnosis, including 52 coded as R26.8 (unsteadiness on the feet). Age ≥ 60 years (adjusted hazard ratio [HR] 4.18; 95% confidence interval [CI] 1.70-10.30), female sex (adjusted HR 1.96; 95% CI 1.16-3.31), and renal failure (adjusted HR 1.93; 95% CI 1.08-3.47) were significantly associated with the outcome. In contrast, liver disease and initial daily MNZ dose > 1500 mg/day showed no significant associations. This study estimated the incidence of newly recorded, database-defined CNS-related diagnoses during and shortly after MNZ therapy and identified age ≥ 60 years, female sex, and renal failure as associated factors in the primary Cox regression analysis. Age ≥ 60 years showed the most consistent association across the sensitivity analyses, whereas the associations with female sex and renal failure were less precise in some analyses. However, these findings do not establish causality or a dose threshold.

PMID 43052617
阅读全文 →
PubMedJournal of medical case reports2026-11-19

Rapid progression of myocardial calcification in a patient presenting with hypercalcemia of unidentified etiology: a case report.

Hirai Shota S, Nishigaito Toshiya T, Mitsumoto Kensuke K, Mizumoto Aya A et al.

Myocardial calcification is an uncommon but clinically important finding that may result in severe cardiac dysfunction. It is generally classified as metastatic calcification triggered by an elevated serum calcium-phosphate product or dystrophic calcification occurring at sites of prior inflammatory or ischemic injury. There are few reports describing dynamic changes in myocardial calcification among patients with hypercalcemia. In addition, hypercalcemia with an unidentified cause has rarely been reported. We encountered a fatal case that developed both metastatic and dystrophic myocardial calcification. This case may contribute to a better understanding of the potential cardiac complications of severe hypercalcemia.Affiliations: Journal instruction requires a city and country for affiliations; however, these are missing in affiliation [2, 3]. Please verify if the provided city and country are correct and amend if necessary.All authors' affiliation addresses are Osaka, Japan. A 57-year-old Japanese woman with a history of asthma presented with nausea and fatigue. She had severe hypercalcemia with acute kidney injury and marked eosinophilia. Intact parathyroid hormone was suppressed (11 pg/mL), with normal parathyroid hormone-related protein and vitamin D metabolites. Fractional excretion of calcium was elevated to 12%. Imaging studies, bone marrow examination, and renal biopsy did not identify a definitive etiology. She was diagnosed with severe hypercalcemia of unidentified etiology complicated by acute kidney injury and eosinophilia. Despite intravenous fluids, calcitonin, and denosumab followed by hemodialysis, she developed progressive respiratory failure and circulatory collapse with myocardial injury and coronary microvascular dysfunction, and serial CT showed new myocardial calcification from day 9 with rapid diffuse progression. She died 22 days after admission despite extracorporeal circulatory support, and autopsy revealed extensive multi-organ calcification including the heart and lungs. Severe hypercalcemia of unidentified etiology can be complicated by extensive myocardial calcification. Ectopic calcification initially induced by hypercalcemia may have been influenced by inflammatory conditions such as eosinophilia. In addition, subsequent myocardial injury may accelerate dystrophic calcification. Clinicians should be aware of the risk of early and progressive cardiac involvement in patients with hypercalcemia, particularly in the presence of inflammatory conditions.

PMID 43053195
阅读全文 →
PubMedLasers in medical science2026-11-19

Er: YAG laser for lip and perioral remodelling with emphasis on SMOOTH® mode: a systematic review of clinical evidence.

Giovannacci Ilaria I, Iaria Roberta R, Maffei Renzo R, Antonelli Rita R et al.

This review aimed to assess the current evidence on the use of Er: YAG laser for non-injective lip and perioral aesthetic remodelling, with emphasis on SMOOTH® mode and to determine whether the reported treatment outcomes reflect true lip-volume augmentation or perceived fullness resulting from tissue remodelling. A systematic literature search was conducted in MEDLINE/PubMed, Web of Science, Scopus, and the Cochrane Library, with no date restrictions. Studies were eligible if they reported clinical outcomes after 2940-nm Er:YAG laser treatment relevant to the lips, labial mucosa, perioral region, nasolabial folds, or anatomically related areas. Risk of bias was assessed using RoB 2 for randomized or split-face randomized studies and ROBINS-I for non-randomized prospective studies. Five studies involving 80 participants across mixed facial cohorts were included; only a subset received labial or isolated perioral treatment. Two studies were classified as Level 2b evidence and two as Level 4 evidence. No study measured objective lip volume, vermilion height, lip projection, Cupid's bow definition or validated lip-specific fullness outcomes. One study measured upper-lip morphology with three-dimensional stereophotogrammetry, reporting shortening of the philtral length and a decreased nasolabial angle, but did not quantify lip volume. Evidence was more consistent for perioral rejuvenation, nasolabial fold remodelling, rhytid reduction, dermal thickening, skin texture improvement, and collagen remodelling. Reported adverse events were generally transient, although post-inflammatory hyperpigmentation and labial herpes simplex reactivation were clinically relevant safety considerations. Current evidence supports Er:YAG laser as a biologically plausible and clinically promising modality for perioral rejuvenation and tissue-quality improvement. However the five eligible studies were heterogeneous, drew on mixed facial cohorts, and only one of them assessed the labial unit directly, measuring upper-lip morphology rather than volumeThe evidence is therefore insufficient to demonstrate true objective lip-volume augmentation - though this does not mean such augmentation does not occur. Er:YAG laser should be described as a non-injective remodelling approach that may enhance perceived fullness through tissue remodelling, rather than as a proven volumetric substitute for injectable fillers, and its effects should not be extrapolated between modalities.

PMID 43052576
阅读全文 →
PubMedClinical oral investigations2026-11-19

Intra-sulcular compound chamomile and lidocaine hydrochloride gel for procedural pain during ultrasonic scaling: a randomized, single-blind, split-mouth, sham-controlled superiority trial in adults with plaque-induced gingivitis.

Tang Rong R, Yin Tingting T, Liang Jia J, Wang Ruijie R et al.

This study aimed to evaluate whether intra-sulcular application of a compound chamomile and lidocaine hydrochloride gel (Kami-Gel) reduces procedural pain during ultrasonic supragingival scaling in adults with plaque-induced gingivitis compared with a sham procedure. A single-center, randomized, single-blind, split-mouth, sham-controlled superiority trial was conducted involving 114 adults with plaque-induced gingivitis. Participants received a sequential split-mouth treatment. The test side received intra-sulcular application of Kami-Gel, while the control side received a sham application (mimicked injection). The primary outcome was procedural pain intensity measured on a 0-10 Visual Analog Scale (VAS). Secondary outcomes included the number of pain complaints, procedural duration, patient satisfaction, and plaque index (PI). Safety was assessed immediately and at 24 h. All 114 participants completed the study. Median VAS score was significantly lower in the test group (1.7 [IQR: 0.62-2.58]) than the control group (4.1 [IQR: 2.42-5.7]), with an estimated treatment difference of - 2.35 (95% CI: -3.0 to - 1.7)-the upper limit of which fell below the pre-specified superiority margin of - 1.2, confirming superiority (P < 0.001). The test group also demonstrated significantly fewer pain complaints (median 0 vs. 1), shorter procedural duration (median 10 vs. 12 min), and higher patient satisfaction (all P < 0.001). Post-scaling plaque index was significantly lower in the test group (median 0.75 [IQR: 0.55-0.86] vs. 0.89 [IQR: 0.75-0.96]; P < 0.001), though this difference may reflect improved patient cooperation rather than a direct pharmacological effect. No adverse events were reported. Intra-sulcular application of compound chamomile and lidocaine hydrochloride gel reduces procedural pain during ultrasonic supragingival scaling compared to a sham procedure. Its use was associated with shorter active scaling time and higher satisfaction. Whether these acute benefits translate to improved long-term periodontal treatment compliance warrants further investigation. Intra-sulcular application of compound chamomile and lidocaine gel (Kami-Gel) prior to ultrasonic supragingival scaling reduces procedural pain and was associated with higher patient satisfaction. A lower post-scaling plaque index was observed in the test group, potentially attributable to improved patient cooperation during instrumentation. This safe, non-injectable chairside technique provides clinicians a practical tool to enhance patient comfort during scaling procedures.

PMID 43052462
阅读全文 →
PubMedBJOG : an international journal of obstetrics and gynaecology2026-11-18

Injectable Hyaluronic Acid for Genitourinary Syndrome of Menopause.

Menabrito Marco M, Calaf Joaquim J

Genitourinary syndrome of menopause (GSM) is a chronic condition resulting from oestrogen deficiency and characterised by persistent genital, sexual, and urinary symptoms that can substantially impair quality of life. While local oestrogen therapy is highly effective, a significant proportion of women are unable or unwilling to use hormonal treatments, highlighting the need for effective non-hormonal options. This narrative review examines local, non-hormonal approaches to GSM, with a particular emphasis on injectable hyaluronic acid-based therapies. Hyaluronic acid is integral to tissue hydration, viscoelasticity, and the maintenance of extracellular matrix integrity, processes that are compromised in GSM. Topical formulations are commonly used to provide surface hydration and symptom relief, while injectable approaches deliver hyaluronic acid to deeper tissue layers; the potential implications for the magnitude and duration of clinical benefit require further evaluation. Among injectable formulations, hybrid cooperative complex hyaluronic acid (HCC-HA) has been evaluated in small prospective studies and one randomised trial in women with sexual dysfunction rather than strictly defined GSM. Available studies report potential improvements in some symptoms, including vaginal dryness and dyspareunia. However, improvements were not demonstrated across all assessed outcomes, including certain sexual-function and quality-of-life measures. No serious adverse events were reported in the available studies, although larger studies with longer follow-up are needed to characterise the safety profile more fully. Injectable hyaluronic acid-based therapies are emerging non-hormonal interventions for vulvovaginal symptoms associated with GSM. Current evidence does not yet establish their role as routine or guideline-recommended treatments. This evidentiary position should be considered separately from the intended purpose and regulatory status of individual devices. Larger independent trials, longer-term safety data, and health-economic evaluations are needed to define their comparative clinical role.

PMID 43051281
阅读全文 →
PubMedInternational journal of reproductive biomedicine2026-11-18

Can injectable glucose-lowering agents affect erectile function in men? A letter to the editor.

Nasirian Mansoureh M

PMID 43047792
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多calcitonin